	US 12,263,197 B2
	Oncolytic virus for cancer therapy
Hiroaki Uchida, Tokyo (JP); and Hideaki Tahara, Tokyo (JP)
Assigned to THE UNIVERSITY OF TOKYO, Tokyo (JP)
Appl. No. 17/288,227
Filed by The University of Tokyo, Tokyo (JP)
PCT Filed Oct. 30, 2019, PCT No. PCT/JP2019/042526 § 371(c)(1), (2) Date Apr. 23, 2021, PCT Pub. No. WO2020/090871, PCT Pub. Date May 7, 2020.
Claims priority of application No. 2018-203553 (JP), filed on Oct. 30, 2018.
Prior Publication US 2021/0386807 A1, Dec. 16, 2021
Int. Cl. A61K 35/763 (2015.01); A61P 35/00 (2006.01)

CPC A61K 35/763 (2013.01) [A61P 35/00 (2018.01)]

18 Claims

1. A virus preparation for the treatment of a cancer, comprising an HSV (herpes simplex virus) having a receptor-retargeted gD mutation and at least one membrane fusion activity-promoting region on the genome,

wherein the membrane fusion activity-promoting region is a region having a syn mutation, and

wherein the syn mutation is a mutation comprising an amino acid mutation at position 858 of SEQ ID NO: 2 which is a substitution with cysteine or histidine.